Trastuzumab deruxtecan emerges as a superior second-line option for HER2-positive metastatic breast cancer, with a fourfold increase in median progression-free survival vs trastuzumab emtansine, as reported in the DESTINY-Breast03 trial.
Nour Abuhadra, MD
Director, Rare Breast Cancer Program, Department of Medicine Co–Section Head, Triple Negative Breast Cancer Clinical Research Program, Department of Medicine Evelyn H. Lauder Breast Center at Memorial Sloan Kettering Cancer Center and Weill Cornell Medicine New York, NY
As a second-line option, trastuzumab deruxtecan (Enhertu; T-DXd) has become a preferred treatment choice in the management of HER2- positive metastatic breast cancer based on updates from the DESTINY-Breast03 trial (NCT03529110). Trial investigators reported that the median progression-free survival (PFS) was about 4 times longer using T-DXd (28.8 months; 95% CI, 22.4-37.9) when compared with trastuzumab emtansine (Kadcyla; T-DM1) (6.8 months; 95% CI, 5.6-8.2), Nour Abuhadra, MD, explained at the 41st Annual Chemotherapy Foundation Symposium Innovative Cancer Therapy for Tomorrow® conference held from November 8 to 10, 2023, in New York.1
“We observed a significant difference in PFS between T-DXd and T-DM1, with T-DXd demonstrating an PFS of 28 months compared with 6.8 months with T-DM1. This extended duration of PFS exceeded historical benchmarks, surpassing the CLEOPATRA trial [NCT00567190] findings in the first-line setting. Moreover, this PFS benefit was consistently evident across various subgroups,” Abuhadra, said. Abuhadra is the director of the Rare Breast Cancer Program in the Department of Medicine, co–section head of the Triple Negative Breast Cancer Clinical Research Program and in the Department of Medicine at Evelyn H. Lauder Breast Center at Memorial Sloan Kettering Cancer Center and Weill Cornell Medicine in New York, New York.
The multicentered phase 3 DESTINY-Breast03 trial, enrolled 524 patients who were randomly assigned 1:1 into 2 arms. Patients in the first arm (n=261) received 5.4 mg/kg of T-DXd every 3 weeks, and patients in the second arm (n=263) received 3.6 mg/kg of T-DM1 every 3 weeks. The primary end point was PFS, and the notable secondary end point was overall survival (OS). The median duration of study follow-up was 28.4 months (22.1-32.9) with T-DXd compared with 26.5 months (14.5-31.3) with T-DM1, and the median PFS by blinded independent central review was 28.8 months (95% CI, 22.4-37.9) with T-DXd and 6.8 months (5.6-8.2; HR, 0.33 [95% CI, 0.26-0.43] P =.0001) with T-DM1. Although the median OS was not reached (95% CI, 40.5 months-not reached), "the 24-month OS was 77% with T-DXd vs 69% with T-DM1, and this is statistically significant,” Abuhadra said.1,2
Among the patients in the study, 100% received prior trastuzumab (Herceptin), 60% received prior pertuzumab (Perjeta), 16% received a HER2 tyrosine kinase inhibitor (TKI), and 50% received 1 line of unspecified therapy for metastatic breast cancer.1 PFS benefit was also observed across subgroups when receiving T-DXd, particularly for patients with brain metastases (n=114). For these patients (n=114), the median PFS was 15.0 months (95% CI, 12.6-22.2) with T-DXd vs 5.7 months (95% CI, 2.9-7.1) with T-DM1 showing an HR of 0.3796 (0.2267-0.6357).
Another trial Abuhadra mentioned was the HER2CLIMB trial (NCT02614794), which also included patients with brain metastasis in the second-line setting. This trial evaluated tucatinib (Tukysa), trastuzumab, and capecitabine (Xeloda) compared with placebo, trastuzumab, and capecitabine. Investigators showed that “the risk of progression in patients with brain metastases was reduced by 52%, and the risk of death in patients with brain metastases was reduced by 42%,” Abuhadra said. The median PFS for patients with brain metastases was 7.6 months (6.2-9.5) in the experimental arm vs 5.4 months (4.1-5.7) with placebo.1,3
“In the second line, our favored agent is T-DXd, especially for patients with active central nervous system disease, while considering the HER2CLIMB regimen. Moving into the third and fourth lines of treatment, we consider utilizing T-DM1 if it hasn’t been previously used, or the HER2CLIMB regimen if not already administered. Additionally, we have TKIs such as margetuximab [Margenza] combined with chemotherapy and trastuzumab combined with chemotherapy, as other viable options,” Abuhadra said.
Leon-Ferre Explores Targeting of PIK3CA Alterations in ER+ Breast Cancer
July 24th 2024During a live Community Case Forum event in partnership with the Minnesota Society of Clinical Oncology, Roberto A. Leon-Ferre, MD, discussed drugs targeting PIK3CA alterations in patients with ER+ metastatic breast cancer.
Read More
George Explores Impact of Risk Status With Cabozantinib/Nivolumab in Advanced RCC
July 19th 2024During a Case-Based Roundtable® event, Daniel George, MD, discussed the results of the CheckMate 9ER trial across favorable, intermediate, and poor risk groups in patients with advanced renal cell carcinoma.
Read More
Rossetti Reviews Myelofibrosis Risk Stratification and Outcome Data for Pacritinib
July 17th 2024During a Case-Based Roundtable® event, James M. Rossetti, DO, discussed the role of risk scoring and stratification tools and treatment for a patient with declining hemoglobin and platelet counts due to primary myelofibrosis.
Read More